Comparative evaluation of cyclosporine A/HPβCD-incorporated PLGA nanoparticles for development of effective ocular preparations

Journal of Microencapsulation

Volumn 29, Issue 6, 2012, Pages 605-613

  Aksungur, Pelin ^a   Demirbilek, Murat ^a   Denkbaş, Emir B ^a   Ünlü, Nurşen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

CsA; Dry eye disease; HP CD; Nanoparticles; PLGA

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CYCLOSPORIN A; NANOPARTICLE; POLYGLACTIN;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; EMULSION; IN VITRO STUDY; INCUBATION TIME; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CELL LINE; CYCLODEXTRINS; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; LACTIC ACID; MICE; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY;

EID: 84865498354     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.668961     Document Type: Article

References (31)

1. Aksungur P, Demirbilek M, Denkbaş BE, Vandervoort J, Ludwig A, ÜnlüN. Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: Cellulat toxicity, uptake, and kinetic studies. J Control Release, 2011;151:286-94.
2. Aktaş Y, ÜnlüN, Orhan M, -Irkeç M,H|ncal AA. Influence of hydroxypropyl-cyclodextrin (HP-CD) on the corneal permeation of pilocarpine. Drug Dev Ind Pharm, 2003;29:223-30. (Pubitemid 36292945)
3. Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: Preparation and in-vitro evaluation. Eur J Pharm Biopharm, 2008;70: 819-82.
4. Belin WM, Bouchard CS, Phillips TM. Update on topical cyclosporin A, background, immunology and pharmacology. Cornea, 1990;9: 184-95. (Pubitemid 20298629)
5. Boudad H, Legrand P, Lebas G, Cheron M, Duche○ne D, Ponchel G. Combined hydroxypropyl-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm, 2001;218:113-24. (Pubitemid 32406162)
6. Brewster ME, Hora MS, Simpkins JW, Bodor N. Use of 2-hydroxypropylbeta- cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res, 1991;8:792-5.
7. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev, 2007;59:645-66. (Pubitemid 47299263)
8. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release, 2007;123:78-99. (Pubitemid 47566400)
9. Challa R, Ahuja A, Ali J, Khar RK. 2005. Cyclodextrins in drug delivery: An updated review. AAPS Pharm Sci Tech, 2005;6:329-7.
10. Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev, 1997;97:1325-57. (Pubitemid 127659601)
11. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit- RS100 or RL100/PLGA nanoparticles. Int J Pharm, 2006;314:72-82.
12. FDA, Center for Drug Evaluation and Research, Guidance for Industry. 1997. Dissolution testing of immediate release solid oral dosage forms. Rockville, USA
13. Frömming KH, Szejtli J. 1994. Cyclodextrins in pharmacy. Dordrecht, The Netherlands: Kluwer Academic Publishersukaya H, Iimura A, Hoshiko K, Fuyumuro T, Noji S, Nabeshima T. A cyclosporin A/maltosyl-a-cyclodextrin complex for inhalation therapy of asthma. Eur Respir J, 2003;22:213-19.
14. Fukaya H, Iimura A, Hoshiko K, Fuyumuro T, Noji S, Nabeshima T. A cyclosporin A/maltosyl-a-cyclodextrin complex for inhalation therapy of asthma. Eur Respir J 200322 213-219
15. Garcia-Fuentes M, Trapani A, Alonso MJ. Protection of the peptide glutathione by complex formation with a-cyclodextrin: NMR spectroscopic analysis and stability st udy. Eur J Pharm Biopharm, 2006;64:146-53. (Pubitemid 44291996)
16. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell-growth cell kill. J Immunol Methods, 1989;119:203-10. (Pubitemid 19132276)
17. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instr, 1965;4:117-212.
18. Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev, 1999;36:101-23. (Pubitemid 29074479)
19. Jin CY, Zhu BS, Wang XF, Lu QH. Cytotoxicity of titanium dioxide nanoparticles in mouse fibroblast cells. Chem Res Toxicol, 2008;21:1871-87.
20. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm, 2003;56:307-18. (Pubitemid 37346503)
21. Laza-Knoerr AL, Gref R, Couvreur P. Cyclodextrins for drug delivery. J Drug Target, 2010;18:645-56.
22. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 1996;85:1017-25. (Pubitemid 26338912)
23. Mannila J, Järvinen K, Holappa J, Matilainen L, Auriola S, Jarho P. Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. Int J Pharm, 2009;381:19-24.
24. Matilainen L, Järvinen K, Toropainen T, Näsi E, Auriola S, Järvinen T, Jarho P. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int J Pharm, 2006;318:41-8. (Pubitemid 43963296)
25. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res, 1996;13:163-7. (Pubitemid 26076314)
26. Miyake K, Hirayama F, Uekama K. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin with dimethyl-alpha-and-beta-cyclodextrins in aqueous solution. J Pharm Sci, 1999;88:39-45. (Pubitemid 29037366)
27. Mura P, Maestrelli F, Cecchi M, Bragagni M, Almeida A. Development of a new delivery system consisting in 'drug-in cyclodextrin-in PLGA nanoparticles'. J Microencapsul, 2010;27:479-86.
28. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs, 1995;50:924-41.
29. Paulsson M, Edsman K. Controlled drug release from gels using surfactant aggregates: I. Effect of lipophilic interactions for a series of uncharged substances. J Pharm Sci, 2001;90:1216-25. (Pubitemid 32867971)
30. Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: Application in different routes of drug administration. Acta Pharm, 2005;55:139-56. (Pubitemid 40992426)
31. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res, 2004;21:2369-76. (Pubitemid 40568453)